Reviva Pharmaceuticals Raises $10M in Public Offering to Fund Schizophrenia Trial — Reviva Pharmaceuticals Holdings, Inc.

Event summary

Reviva Pharmaceuticals priced a $10M public offering of 6.67M shares of common stock and accompanying warrants.
The offering includes Series G and Series H warrants with exercise prices of $1.50 per share.
Proceeds will fund the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia and general corporate purposes.
The offering is expected to close on March 20, 2026, subject to customary closing conditions.

The big picture

Reviva Pharmaceuticals' $10M public offering underscores the financial pressures facing late-stage biopharmaceutical companies as they navigate the costly Phase 3 trial process. The funding will be critical for advancing brilaroxazine, a potential treatment for schizophrenia, in a competitive CNS therapeutic landscape. The strategic move highlights the balance between securing non-dilutive capital and maintaining operational independence.

What we're watching

Clinical Trial Progress: How the RECOVER-2 Phase 3 trial for brilaroxazine will impact Reviva's strategic positioning in the schizophrenia treatment market.
Financial Flexibility: Whether the $10M raised will be sufficient to sustain Reviva's R&D activities and working capital needs.
Market Reception: The pace at which Reviva can convert the proceeds into tangible clinical and commercial milestones.